Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.33M.
Overvalued
The company’s latest PE is 4.57, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 317.36M shares, increasing 0.24% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 50.85M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.91.